ClinicalTrials.gg
CompletedNCT00633464Updated Mar 10, 2016Results posted

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

A Phase 2 interventional study of ixabepilone and ixabepilone + cetuximab in Triple Negative Locally Advanced Non-resectable Breast Cancer and Metastatic Breast Cancer, sponsored by R-Pharm. Completed at 19 sites in 7 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-10.

Sponsored by R-Pharm · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies testing ixabepilone in Breast Neoplasms — none open to participants now, 1 under way, none of them phase 3. ixabepilone · Breast Neoplasms.

Enrollment
15th of 39
79 · median 56
Started
2008
with 10 others
Phase 2
24 of 41
none open now
Registered
18th of 41
by date
Lead sponsor
13 of 41
R-Pharm

Among the 41 studies testing ixabepilone in Breast Neoplasms, this one is the 15th largest by enrollment of the 39 interventional ones that give a count, is one of 11 that started in 2008, is one of 24 in phase 2, and was the 18th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 41 studies testing ixabepilone in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About ixabepilone

ixabepilone: first FDA approval 2007 (IXEMPRA KIT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 41 studies testing ixabepilone in Breast Neoplasms as a file.
02

Study summary

The purpose of this study was to estimate the response rate of ixabepilone monotherapy, and the combination of ixabepilone plus cetuximab as first-line treatment of female subjects with triple negative (estrogen receptor [ER], progesterone receptor [PR], Human Epidermal Growth Factor Receptor 2 [HER2] negative) locally advanced non-resectable and/or metastatic breast cancer

03

Conditions studied

  • Triple Negative Locally Advanced Non-resectable Breast Cancer
  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects with triple negative (ER, PR, and negative) locally advanced non-resectable and/or breast cancer
  • Prior or neoadjuvant anthracycline-based chemotherapy

Exclusion criteria

Exclusion Criteria:

  • Tumors that are fluorescence in situ hybridization test (FISH) positive or immunohistochemistry (IHC) 3+
  • Neuropathy > Grade 1
  • Prior systemic therapy for disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    Arm A (ixabepilone 40 mg^2)

    ixabepilone 40 mg/m\^2 every 3 weeks

    Drug: ixabepilone

  • Experimental
    Arm B (cetuximab 250 mg/m^2 + ixabepilone 40 mg/m^2)

    cetuximab 400 mg/m\^2 loading dose then 250 mg/m\^2 weekly + ixabepilone 40 mg/m\^2 every 3 weeks

    Drug: ixabepilone + cetuximab

Interventions

  • injection, intravenous (IV), until unacceptable toxicity or progression or 15 months after the Last Subject First Visit (LSFV), whichever comes first. Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant met the re-treatment criteria.

    Also known as: IXEMPRA, BMS-247550

  • Drugixabepilone + cetuximab

    Drug pages: Ixabepilone · Cetuximab

    Ixabepilone: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first. Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant meets the re-treatment criteria. Cetuximab: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first. Cetuximab 400 mg/m\^2 was administered as a 2-hour IV loading dose via in-line filtration with an infusion pump, gravity drip, or a syringe pump on Day 1 of first cycle then 250 mg/m\^2 1-hour IV once a week, i.e. on Days 1, 8, and 15 of each cycle provided the participant meets the re-treatment criteria.

    Also known as: IXEMPRA, BMS-247550, ERBITUX, BMS-564717

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST])

    The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions. Confidence interval (CI) was Computed using Clopper-Pearson method.

    Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks)

  2. Number of Participants With Best Overall Response as Assessed With Response Criteria in Solid Tumors (RECIST)

    PD = At least a 20% increase in the sum of LD of target lesions in reference to the smallest sum LD recorded at or following baseline or unequivocal progression of existing non-target lesion(s) overall; Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions.

    Time frame: Assessed at 6 week intervals for first 12 months from randomization, thereafter every 3 months (to a maximum follow-up for tumor response of 17 months).

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time interval from date of randomization until the first date of documented progressive disease (PD) or death from any cause without prior documentation of progression. The PFS was estimated using the Kaplan-Meier product-limit method, and a two-sided 95% CI for the median PFS time was computed using the method of Brookmeyer and Crowley. PD: At least 20% increase in sum of LD of target lesions in reference to smallest sum LD recorded at or following baseline or unequivocal progression of existing non-target lesion(s) overall.

    Time frame: From the date of randomization to date of progression, death, or last tumor assessment (maximum participant PFS of 17 months)

  2. Time to Response

    Time to response is defined as the time from the date of start of treatment until measurement criteria are first met for PR or CR (whichever is recorded first). CR: Disappearance of all target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the LD of all target lesions with reference to the baseline sum LD. Time to response was estimated using the Kaplan-Meier product-limit method.

    Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until CR or PR (maximum participant time to response of 18.3 weeks.)

  3. Duration of Response

    Defined as period from the time that measurement criteria are first met for CR or PR until first date of documented PD or death. Estimated using the Kaplan-Meier product-limit method; CI was computed using Brookmeyer and Crowley method. CR: Disappearance of all target and non-target lesions. PR: At least 30% reduction from baseline in the sum of LD of all target lesions with reference to baseline sum LD. PD: At least 20% increase in sum of LD of target lesions in reference to smallest sum LD recorded at or following baseline or unequivocal progression of existing non-target lesion(s) overall.

    Time frame: From the date of first PR or CR assessment to date of progression, death, or last tumor assessment (maximum participant duration of response of 15.6 months)

  4. Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs), and AEs Leading to Discontinuation of Study Therapy Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0

    AE: New untoward medical occurrence or worsening of a preexisting medical condition that does not have causal relationship with this treatment. SAE: Untoward medical event that at any dose: results in death, persistent or significant disability/incapacity, drug dependency/abuse; life-threatening, an important medical event, a congenital anomaly/birth defect; requires inpatient hospitalization/prolongs existing hospitalization. Grade (GR) 3=Severe; and GR4=Life-threatening or disabling. Other reasons for death included hepatic failure and respiratory distress.

    Time frame: Assessed from the date of first dose until at least 30 days after the last dose of study drug. Median time on ixapebilone therapy was 15 weeks (range: 3-54 weeks for ixabepilone arm; 3-36 weeks for ixabepilone+cetuximab arm)

  5. Number of Participants With Hematology Abnormalities

    Grading: NCI CTCAE, Version 3.0. GR1=mild, GR2=moderate, GR3=severe, GR4=life threatening or disabling. Normal ranges provided by local laboratory and may also vary by age and sex. Hemoglobin:GR1=\<LLN-10.0g/dL; GR2=\<10.0-8.0g/dL; GR3:\<8.0-6.5g/dL, GR4:\<6.5g/dL. Platelets:GR1=\<LLN-75.0\*10\^9/L; GR2=\<75.0-50.0\*10\^9/L; GR3:\<50.0-25.0\*10\^9/L, GR4:\<25.0\*10\^9/L. Absolute Neutrophil Count (ANC):GR1=\<LLN-1.5\*10\^9 /L; GR2=\<1.5-1.0\*10\^9/L; GR3:\<1.0-0.5\*10\^9/L; GR4:\<0.5\*10\^9/L. White blood cell (WBC):GR1=\<LLN-3.0\*10\^9/L; GR2=\<3.0-2.0\*10\^9/L; GR3:\<2.0-1.0\*10\^9/L; GR4:\<1.0\*10\^9/L. LLN=lower limit of normal.

    Time frame: Assessed prior to 1st cycle, at beginning of each cycle, weekly (cetuximab treatment), and every 4 weeks within 30 days after last dose of study drug. Median time on ixapebilone therapy: 15 weeks (range:3-54:ixabepilone arm;3-36:ixapebilone+cetuximab arm)

  6. Number of Participants With Serum Chemistry Abnormalities

    Grading: NCI CTCAE, Version 3.0. GR1=mild, GR2=moderate, GR3=severe, GR4=life threatening or disabling. Normal ranges provided by local laboratory and may also vary by age and sex. Alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase: GR1=\>ULN-2.5\*ULN (upper limit of normal); GR2=\>2.5-5.0\*ULN; GR3=\>5.0-20.0\*ULN; GR4:\>20.0\*ULN. Total bilirubin:GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3-10\*ULN, GR4=\>10\*ULN. Creatinine: GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3.0-6.0\*ULN, GR4=\>6.0\*ULN.

    Time frame: Assessed prior to 1st cycle, at beginning of each cycle, weekly (cetuximab treatment), and every 4 weeks within 30 days after last dose of study drug. Median time on ixapebilone therapy: 15 weeks (range:3-54:ixabepilone arm;3-36:ixapebilone+cetuximab arm)

07

Results

Posted Apr 24, 2012

Participant flow

Participant flow — Overall Study
MilestoneIxabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2
Started4039
Treated4037
Completed4037
Not completed02
Withdrew: Never treated (not met study criteria)01
Withdrew: Never treated (randomized in error)01

Outcome measures

SecondaryProgression Free Survival (PFS)

PFS is defined as the time interval from date of randomization until the first date of documented progressive disease (PD) or death from any cause without prior documentation of progression. The PFS was estimated using the Kaplan-Meier product-limit method, and a two-sided 95% CI for the median PFS time was computed using the method of Brookmeyer and Crowley. PD: At least 20% increase in sum of LD of target lesions in reference to smallest sum LD recorded at or following baseline or unequivocal progression of existing non-target lesion(s) overall.

Time frame:
From the date of randomization to date of progression, death, or last tumor assessment (maximum participant PFS of 17 months)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsIxabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2
Progression Free Survival (PFS)4.1 (3.0 to 4.9)4.1 (2.7 to 6.1)
SecondaryTime to Response

Time to response is defined as the time from the date of start of treatment until measurement criteria are first met for PR or CR (whichever is recorded first). CR: Disappearance of all target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the LD of all target lesions with reference to the baseline sum LD. Time to response was estimated using the Kaplan-Meier product-limit method.

Time frame:
Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until CR or PR (maximum participant time to response of 18.3 weeks.)
Reported as:
Median · weeks
Time to Response
weeksIxabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2
Time to Response8.8 (5.1 to 12.0)6.5 (5.1 to 18.3)
PrimaryPercentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST])

The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions. Confidence interval (CI) was Computed using Clopper-Pearson method.

Time frame:
Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST])
percentage of participantsIxabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2
Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST])30.0 (16.6 to 46.5)35.9 (21.2 to 52.8)
SecondaryDuration of Response

Defined as period from the time that measurement criteria are first met for CR or PR until first date of documented PD or death. Estimated using the Kaplan-Meier product-limit method; CI was computed using Brookmeyer and Crowley method. CR: Disappearance of all target and non-target lesions. PR: At least 30% reduction from baseline in the sum of LD of all target lesions with reference to baseline sum LD. PD: At least 20% increase in sum of LD of target lesions in reference to smallest sum LD recorded at or following baseline or unequivocal progression of existing non-target lesion(s) overall.

Time frame:
From the date of first PR or CR assessment to date of progression, death, or last tumor assessment (maximum participant duration of response of 15.6 months)
Reported as:
Median · months
Duration of Response
monthsIxabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2
Duration of Response4.5 (3.0 to 8.7)4.5 (3.4 to 6.9)
SecondaryNumber of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs), and AEs Leading to Discontinuation of Study Therapy Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0

AE: New untoward medical occurrence or worsening of a preexisting medical condition that does not have causal relationship with this treatment. SAE: Untoward medical event that at any dose: results in death, persistent or significant disability/incapacity, drug dependency/abuse; life-threatening, an important medical event, a congenital anomaly/birth defect; requires inpatient hospitalization/prolongs existing hospitalization. Grade (GR) 3=Severe; and GR4=Life-threatening or disabling. Other reasons for death included hepatic failure and respiratory distress.

Time frame:
Assessed from the date of first dose until at least 30 days after the last dose of study drug. Median time on ixapebilone therapy was 15 weeks (range: 3-54 weeks for ixabepilone arm; 3-36 weeks for ixabepilone+cetuximab arm)
Reported as:
Number · participants
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs), and AEs Leading to Discontinuation of Study Therapy Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0
participantsIxabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2
All Deaths89
Deaths due to Disease Progression87
Deaths due to Other Reasons02
At least one SAE (Any Grade)912
At least one SAE (Grade 3 to 4)411
At least one Related SAE (Any Grade)36
At least one Related SAE (Grade 3 to 4)26
At least one AE (Any Grade)4037
At least one AE (Grade 3 to 4)2125
At least one Related AE3737
At least one Related AE (Grade 3 to 4)1822
AEs leading to discontinuation (Any Grade)813
AEs leading to discontinuation (Grade 3 to 4)37
SecondaryNumber of Participants With Hematology Abnormalities

Grading: NCI CTCAE, Version 3.0. GR1=mild, GR2=moderate, GR3=severe, GR4=life threatening or disabling. Normal ranges provided by local laboratory and may also vary by age and sex. Hemoglobin:GR1=\<LLN-10.0g/dL; GR2=\<10.0-8.0g/dL; GR3:\<8.0-6.5g/dL, GR4:\<6.5g/dL. Platelets:GR1=\<LLN-75.0\*10\^9/L; GR2=\<75.0-50.0\*10\^9/L; GR3:\<50.0-25.0\*10\^9/L, GR4:\<25.0\*10\^9/L. Absolute Neutrophil Count (ANC):GR1=\<LLN-1.5\*10\^9 /L; GR2=\<1.5-1.0\*10\^9/L; GR3:\<1.0-0.5\*10\^9/L; GR4:\<0.5\*10\^9/L. White blood cell (WBC):GR1=\<LLN-3.0\*10\^9/L; GR2=\<3.0-2.0\*10\^9/L; GR3:\<2.0-1.0\*10\^9/L; GR4:\<1.0\*10\^9/L. LLN=lower limit of normal.

Time frame:
Assessed prior to 1st cycle, at beginning of each cycle, weekly (cetuximab treatment), and every 4 weeks within 30 days after last dose of study drug. Median time on ixapebilone therapy: 15 weeks (range:3-54:ixabepilone arm;3-36:ixapebilone+cetuximab arm)
Reported as:
Number · participants
Number of Participants With Hematology Abnormalities
participantsIxabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2
White Blood cell (WBC) GR 1-43334
WBC GR 3-41316
Absolute Neutrophil Count(ANC) GR 1-4 (n=39; n=37)3331
ANC GR 3-4 (n=39; n=37)1918
Platelet Count GR 1-4 (n=39; n=37)114
Platelet Count GR 3-4 (n=39; n=37)00
Hemoglobin GR 1-42927
Hemoglobin GR 3-400
PrimaryNumber of Participants With Best Overall Response as Assessed With Response Criteria in Solid Tumors (RECIST)

PD = At least a 20% increase in the sum of LD of target lesions in reference to the smallest sum LD recorded at or following baseline or unequivocal progression of existing non-target lesion(s) overall; Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions.

Time frame:
Assessed at 6 week intervals for first 12 months from randomization, thereafter every 3 months (to a maximum follow-up for tumor response of 17 months).
Reported as:
Number · participants
Number of Participants With Best Overall Response as Assessed With Response Criteria in Solid Tumors (RECIST)
participantsIxabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2
Complete Response30
Partial Response914
Stable Disease1712
Progressive Disease910
Never Treated02
Unable to determine21
SecondaryNumber of Participants With Serum Chemistry Abnormalities

Grading: NCI CTCAE, Version 3.0. GR1=mild, GR2=moderate, GR3=severe, GR4=life threatening or disabling. Normal ranges provided by local laboratory and may also vary by age and sex. Alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase: GR1=\>ULN-2.5\*ULN (upper limit of normal); GR2=\>2.5-5.0\*ULN; GR3=\>5.0-20.0\*ULN; GR4:\>20.0\*ULN. Total bilirubin:GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3-10\*ULN, GR4=\>10\*ULN. Creatinine: GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3.0-6.0\*ULN, GR4=\>6.0\*ULN.

Time frame:
Assessed prior to 1st cycle, at beginning of each cycle, weekly (cetuximab treatment), and every 4 weeks within 30 days after last dose of study drug. Median time on ixapebilone therapy: 15 weeks (range:3-54:ixabepilone arm;3-36:ixapebilone+cetuximab arm)
Reported as:
Number · participants
Number of Participants With Serum Chemistry Abnormalities
participantsIxabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2
Alkaline Phosphatase (ALP) GR 1-4 (n=38; n=35)917
ALP GR 3-4 (n=38; n=35)01
Alanine Aminotransferase (ALT) GR 1-4 (n=39; n=35)1018
ALT GR 3-4 (n=39; n=35)10
Aspartate Aminotransferase (AST) GR1-4(n=39; n=35)1117
AST GR 3-4 (n=39; n=35)13
Total Bilirubin GR 1-4 (n=39; n=35)13
Total Bilirubin GR 3-4 (n=39; n=35)10
Creatinine GR 1-4 (n=40; n=36)31
Creatinine GR 3-4 (n=40; n=36)00

Adverse events

Collected over Assessed from the date of first dose until at least 30 days after the last dose of study drug (Median number of ixabepilone cycles were 5 [range: 1-18 cycles for ixabepilone arm; 1-12 cycles for cetuximab + ixabepilone arm]). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixabepilone 40 mg/m^2—9/40 (22.5%)40/40 (100%)
Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2—12/37 (32.4%)37/37 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventIxabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2
DYSPNOEARespiratory, thoracic and mediastinal disorders0/405/37
TACHYCARDIACardiac disorders0/402/37
FEBRILE NEUTROPENIABlood and lymphatic system disorders0/402/37
NEUTROPENIABlood and lymphatic system disorders0/402/37
PYREXIAGeneral disorders2/400/37
NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/400/37
STOMATITISGastrointestinal disorders0/401/37
VOMITINGGastrointestinal disorders1/401/37
ABDOMINAL PAINGastrointestinal disorders0/401/37
CHEST PAINGeneral disorders0/401/37
Most frequent other events
Showing 10 of 87
Most frequent other events
EventIxabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2
ALOPECIASkin and subcutaneous tissue disorders23/4013/37
ASTHENIAGeneral disorders17/4020/37
NAUSEAGastrointestinal disorders13/4019/37
NEUTROPENIABlood and lymphatic system disorders18/4019/37
PERIPHERAL SENSORY NEUROPATHYNervous system disorders17/4017/37
ACNESkin and subcutaneous tissue disorders0/4015/37
DRY SKINSkin and subcutaneous tissue disorders3/4015/37
DIARRHOEAGastrointestinal disorders4/4014/37
VOMITINGGastrointestinal disorders15/4011/37
MYALGIAMusculoskeletal and connective tissue disorders15/406/37

Baseline characteristics

Age, Customized
Age, Customized(years)Ixabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2Total
Median53.0 (29.0 to 75.0)50.0 (31.0 to 79.0)53.0 (29.0 to 79.0)
Age, Customized
Age, Customized(participants)Ixabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2Total
< 65353267
>=655712
Sex/Gender, Customized
Sex/Gender, Customized(participants)Ixabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2Total
Female403979
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ixabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2Total
White393978
Black/African American101
Karnofsky Performance Status
Karnofsky Performance Status(participants)Ixabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2Total
100232346
906511
80111021
Not Reported011
Setting of Prior Chemotherapy
Setting of Prior Chemotherapy(participants)Ixabepilone 40 mg/m^2Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2Total
Adjuvant therapy282250
Neo-adjuvant therapy202040
Adjuvant and Neo-adjuvant8311
08

Study locations

19 sites
  • Local Institution
    Graz, 8036, Austria
  • Local Institution
    Wien, 1090, Austria
  • Local Institution
    Brno, 656 53, Czech Republic
  • Local Institution
    Prague 5, 150 06, Czech Republic
  • Local Institution
    Praha 2, 128 08, Czech Republic
  • Local Institution
    Bayonne, 64100, France
  • Local Institution
    Dijon Cedex, 21079, France
  • Local Institution
    Lyon, 69008, France
  • Local Institution
    Paris Cedex 13, 75651, France
  • Local Institution
    Saint Brieuc, 22015, France
  • Local Institution
    Saint Herblain Cedex, 44805, France
  • Local Institution
    Toulouse Cedex, 31052, France
  • Local Institution
    Thessaloniki, 54642, Greece
  • Local Institution
    Napoli, 80131, Italy
  • Local Institution
    Gdansk, 80952, Poland
  • Local Institution
    Olsztyn, 10-513, Poland
  • Local Institution
    Barcelona, 08036, Spain
  • Local Institution
    Barcelona, 08208, Spain
  • Local Institution
    Barcelona, 08221, Spain
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Sep 2010 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2008
First posted
Mar 12, 2008
Start
Jun 2008
Primary completionActual
Sep 2010
CompletionActual
May 2011
Results first posted
Apr 24, 2012
Last update
Mar 10, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00633464
Lead sponsor
R-Pharm
Responsible party
Sponsor
First posted
Mar 12, 2008
Start date
Jun 2008
Primary completion
Sep 2010
Completion
May 2011
Results posted
Apr 24, 2012
Last update
Mar 10, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ixabepilone · Cetuximab

Start the discussion